Preclinical R&D Services

Preclinical R&D Services: Large Animal Models

Clinical R&D Services

Pipeline

About pharmahungary group

Pharmahungary Group is a group of R&D companies developing novel in-house R&D projects for valorization (co-development/out-licensing) as well as providing innovative preclinical (nonclinical) and clinical R&D services with strong scientific and regulatory support.

Preclinical r&d services

Innovative and cost-effective preclinical (nonclinical) CRO services from cells to large animal models focusing on cardiovascular (infarct size, heart failure, sepsis, stroke etc.), metabolic (diabetes, hyperlipidemia, atherosclerosis, obesity etc.), renal, inflammation, and neuropathy diseases.

Cardiovascular platform

Innovative preclinical R&D services from cells to large animal models including e.g. porcine and Göttingen minipig models of several cardiovascular diseases.

Metabolic platform

Several diet-induced, toxin-induced, and genetic models of metabolic diseases including but not limited to e.g. diabetes, metabolic disease, hyperlipidemia, atherosclerosis, obesity, uremia.

Clinical r&d services

Clinical R&D services focusing on clinical trials with medical devices, In Vitro Diagnostics, combination products, and drugs including small molecules as well as biologics and Advanced Therapy Medicinal Products (ATMPs). Expertise includes managing Investigator Initiated Trials, and niche trials that need strong scientific and regulatory support due to e.g. sensitive patient population.

Medical devices

Pharmahungary Group clinical R&D services are focusing on medical device/drug/biologics combination clinical trials. Full CRO service in consulting and conducting clinical trials, e.g. feasibility studies, National Competent Authority and Ethics Committee submission, monitoring, site management, contract management from study start-up to closure.

Investigator initiated trials

Preclinical scientific management and clinical/regulatory experts of Pharmahungary Group are supporting manufacturers and research professionals starting Investigator Initiated Trials together. Explore the benefits of Investigator Initiated Trials with Pharmahungary Group.

Pipeline

Pharmahungary Group has several novel in-house R&D projects to develop new diagnostics and therapeutics. These projects are open for out-licensing, co-development, and investment.

Drug development projects

1. ProtectomiR: several cytoprotective miRNA targets, see www.protectomir.com.

Diagnostic R&D projects

1. Infarnosys: novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury, see www.infarnosys.com.
2. Vezics: modular and scalable chromatography platform for high-quality exosome isolation, see www.vezics.com.

Bioinformatics tools

1. miRNAtarget: bioinformatics project for target prediction, see www.mirnatarget.com.
2. Vigilace: bioinformatics project for prediction and determination of previously unknown adverse events and drug interactions, see www.vigilace.com.
3. InfarctSizeAI: automatic, Artificial Intelligence assisted analysis of infarct regions and sizes on stained small and large animal heart images, see www.infarctsize.com.

News

news

Horizon Europe grants

Pharmahungary Group as a Hungarian SME is ready to join Horizon Europe grant applications with innovative preclinical and clinical R&D services.

news

Pharmahungary Group press release – EVEREST Project Aims to Revolutionise Biomedical Research with Extracellular Vesicles in 2025

Pharmahungary Group joins prestigious grant consortium.

event

Founder & CEO attends the 30th BIO Europe conference

Meet us at the 30th BIO Europe conference in Stockholm, Sweden.

news

Founder & CEO of Pharmahungary Group, has been recognized as a ‘Highly Cited Researcher’ for the sixth time in 2023

After after 2014, 2017, 2020, 2021, and 2022 Founder & CEO is ‘Highly Cited Researcher’ again

Megszakítás